Table 1.

Visit and assessment schedule

Items	Screen	Day 1	Day 7 ± 1	Day 14 ± 1	Day 28 ± 3	Day 90 ± 7	Day 180 ± 7
Informed consent	×
Inclusion/exclusiona	×
Filling general information	×
Collect medical history	×
Concomitant medicationsb	×	×	×	×	×
Physical examination	×
Surgery		×	×	×	×	×	×
Neurological symptomsc	×	×	×	×	×	×	×
Haematoma volumec	×			×	×	×
mRSc	×				×	×	×
ADL-BI					×	×	×
Blood routine	×	×		×	×
Biochemistry	×	×		×	×
Coagulation	×	×		×	×
Vital signsc	×	×	×	×	×
Electrocardiography	×			×	×
Adverse events		×	×	×	×	×	×
Allocate random number	×
Drug recyclingd	×	×	×	×	×

ADL-BI activities of daily life on the Barthel Index, mRS modified Rankin scale

^aAccreditation of laboratory examination within 3 days, including head CT, before enrolment

^bCombined use of drugs before commencing study treatment and continue until the end of the 28-day treatment period

^cDuring conservative treatment, if a participant’s neurological function deteriorates associated with an increase in the size of the haematoma and risk of cerebral herniation, they must change over to surgical treatment

^dRemaining drugs are to be recycled